AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23599170 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 196
Study 22409849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation treatment
Number of subjects: 190
Study 22409849 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study 19123148 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-site phacotrabeculectomy
Number of subjects: 58
Study 19123148 — intervention group
Group type: COMPARATOR
Intervention: MICS + trabeculectomy
Number of subjects: 58
Study 17699388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage enoxaparin
Number of subjects: 10
Study 17699388 — intervention group
Group type: COMPARATOR
Intervention: AngII infusion
Number of subjects: 10
Study 17699388 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 10
Study 15507176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab added to chemotherapy
Number of subjects: 469
Study 15507176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab added to anthracycline (doxorubicin or epirubicin) plus cyclophosphamide (AC)
Number of subjects: 469
Study 15507176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab added to paclitaxel
Number of subjects: 469
Study 15507176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab added to AC
Number of subjects: 469
Study 11593955 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement
Number of subjects: 18
Study 11593955 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Noise
Number of subjects: 18
Study 11593955 — intervention group
Group type: COMPARATOR
Intervention: Exposure Alone
Number of subjects: 18
Study 11593955 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline to Post exposure
Number of subjects: 18
Study 9610080 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with CHD
Number of subjects: 103
Study 9610080 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics without CHD
Number of subjects: 103
Study 9610080 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 103
Study 9610080 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 103
Study 9610080 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with CHD vs Diabetics without CHD
Number of subjects: 103
Study 9610080 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM vs IDDM
Number of subjects: 103
Study 9610080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 8072077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methyltestosterone (2 different commercial preparations) for 1 month
Number of subjects: 22
Study 3292630 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lidocaine strategy
Number of subjects: 333
Study 3292630 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective lidocaine strategy
Number of subjects: 333
Study 31402742 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse prism (IP) therapy
Number of subjects: 100
Study 31402742 — intervention group
Group type: COMPARATOR
Intervention: Conventional prism (CP) therapy
Number of subjects: 100
Study 25887660 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-Up-and-Go Test (TUG)
Number of subjects: 259
Study 23687227 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope® video laryngoscope (GVLs)
Number of subjects: 23
Study 23687227 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope (DL)
Number of subjects: 23
Study 21355718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal microneedle delivery of insulin lispro (IL)
Number of subjects: 10
Study 18536954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (15 then 30 mg/day)
Number of subjects: 17
Study 18536954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16890577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir (400 mg twice daily)/ritonavir (100 mg twice daily)
Number of subjects: 24
Study 16890577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg twice daily (after dose adjustment)
Number of subjects: 24
Study 16890577 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine 50 mg once daily on days 1 and 2 and 100 mg twice daily on day 3 through day 10
Number of subjects: 24
Study 16890577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 2N‐glucuronide to lamotrigine
Number of subjects: 24
Study 15612851 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical workshop only
Number of subjects: 140
Study 15612851 — intervention group
Group type: EXPERIMENTAL
Intervention: workshop plus practice feedback
Number of subjects: 140
Study 15612851 — intervention group
Group type: EXPERIMENTAL
Intervention: workshop plus individual coaching sessions
Number of subjects: 140
Study 15612851 — intervention group
Group type: EXPERIMENTAL
Intervention: workshop, feedback, and coaching
Number of subjects: 140
Study 15612851 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group of self‐guided training
Number of subjects: 140
Study 11359886 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine dressing
Number of subjects: 42
Study 11359886 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous hydrogel dressing (Intrasite Gel)
Number of subjects: 42
Study 11359886 — intervention group
Group type: COMPARATOR
Intervention: Control dressing (paraffin gauze)
Number of subjects: 42
Study 8988823 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 121
Study 8988823 — intervention group
Group type: COMPARATOR
Intervention: Relaxing suggestions
Number of subjects: 121
Study 8988823 — intervention group
Group type: COMPARATOR
Intervention: White noise
Number of subjects: 121
Study 8988823 — intervention group
Group type: COMPARATOR
Intervention: Operating room noise
Number of subjects: 121
Study 8267175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 ng/mL
Number of subjects: 79
Study 8267175 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 28.8 ng/mL
Number of subjects: 79
Study 8267175 — intervention group
Group type: COMPARATOR
Intervention: No opioid (control)
Number of subjects: 79
Study 3311051 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone subacromial bursa injection
Number of subjects: 100
Study 3311051 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen therapy
Number of subjects: 100
Study 3311051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31892574 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia
Number of subjects: 56
Study 31892574 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose RSB analgesia
Number of subjects: 56
Study 31892574 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 56
Study 31892574 — intervention group
Group type: EXPERIMENTAL
Intervention: RSB analgesia in cancer patients
Number of subjects: 56
Study 30470591 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing regimens
Number of subjects: 3223
Study 30470591 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-containing regimens
Number of subjects: 3223
Study 27398889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine for 72 hours
Number of subjects: 48
Study 27398889 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 72 hours
Number of subjects: 48
Study 25736126 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 0.3 micro;g/kg followed by propofol 1 mg/kg (group D)
Number of subjects: 90
Study 25736126 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg/kg (group C)
Number of subjects: 90
Study 23263721 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 70
Study 20411230 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior minimally invasive (MIS) approach
Number of subjects: 109
Study 20411230 — intervention group
Group type: COMPARATOR
Intervention: Regular transgluteal (TG) approach
Number of subjects: 109
Study 19906340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (2-15 mg/d)
Number of subjects: 323
Study 19906340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 19906340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 323
Study 19906340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (in risperidone subgroup)
Number of subjects: 323
Study 19906340 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in risperidone subgroup)
Number of subjects: 323
Study 19906340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (in quetiapine subgroup)
Number of subjects: 323
Study 19906340 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in quetiapine subgroup)
Number of subjects: 323
Study 17692117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion (0.05 units/kg/h)
Number of subjects: 500
Study 17692117 — intervention group
Group type: COMPARATOR
Intervention: Standard neonatal care
Number of subjects: 500
Study 15893156 — intervention group
Group type: EXPERIMENTAL
Intervention: Early onset inhalant use (initiated before age 14)
Number of subjects: 2311
Study 15893156 — intervention group
Group type: COMPARATOR
Intervention: No inhalant use (control group)
Number of subjects: 2311
Study 12487852 — intervention group
Group type: EXPERIMENTAL
Intervention: (186)Re-lipiodol (RL) administered at doses ranging from 1 110 MBq to 2 220 MBq per patient depending on tumor volume.
Number of subjects: 0
Study 12487852 — intervention group
Group type: EXPERIMENTAL
Intervention: (186)Re-lipiodol (RL)
Number of subjects: 0
Study 9793223 — intervention group
Group type: EXPERIMENTAL
Intervention: TF index
Number of subjects: 325
Study 9793223 — intervention group
Group type: EXPERIMENTAL
Intervention: modified DDE index
Number of subjects: 325
Study 7636556 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 20-mg IV dose of dexamethasone plus single 32-mg IV dose of ondansetron
Number of subjects: 146
Study 7636556 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 20-mg IV dose of dexamethasone plus single 24-mg IV dose of ondansetron
Number of subjects: 146
Study 7636556 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 20-mg IV dose of dexamethasone plus single 8-mg IV dose of ondansetron
Number of subjects: 146
Study 7636556 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events across all groups
Number of subjects: 146
Study 2236435 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/Kg b.i.d.)
Number of subjects: 0
Study 2236435 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose b.i.d.)
Number of subjects: 0
Study 27093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolaids (2 tablets)
Number of subjects: 32
Study 27093 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-Gel (2 tablets)
Number of subjects: 32
Study 27093 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox liquid (15 ml)
Number of subjects: 32
Study 27093 — intervention group
Group type: EXPERIMENTAL
Intervention: Conquel (2 tablets)
Number of subjects: 32
Study 29668990 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (PCT)
Number of subjects: 88
Study 29668990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27784414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Insomnia Therapy (CBT-I)
Number of subjects: 104
Study 27784414 — intervention group
Group type: COMPARATOR
Intervention: Quasi-desensitization Control (CTRL) therapy
Number of subjects: 104
Study 27784414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (escitalopram, sertraline, desvenlafaxine) with either CBT-I or CTRL
Number of subjects: 104
Study 25332091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral nutrition group
Number of subjects: 83
Study 25332091 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported exercise paired with cognitive-behavioral approach
Number of subjects: 83
Study 25332091 — intervention group
Group type: COMPARATOR
Intervention: Supported exercise paired with educational approach
Number of subjects: 83
Study 25332091 — intervention group
Group type: EXPERIMENTAL
Intervention: Completing at least two sessions of exercise per week
Number of subjects: 83
Study 22785552 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (1.25-2.5 ng/kg/min)
Number of subjects: 185
Study 22785552 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 185
Study 20706751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride (NaCl) for 60 s
Number of subjects: 39
Study 20706751 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium hypochlorite (NaOCl) for 60 s
Number of subjects: 39
Study 20706751 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% ethylenediaminetetraacetic acid (EDTA) for 60 s followed by 5.25% NaOCl for 60 s
Number of subjects: 39
Study 20706751 — intervention group
Group type: EXPERIMENTAL
Intervention: DUO‐LINK cement
Number of subjects: 39
Study 20706751 — intervention group
Group type: COMPARATOR
Intervention: LuxaCore Dual cement
Number of subjects: 39
Study 17875551 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 102
Study 17875551 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 102
Study 17051601 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 with para-aortic lymph node dissection
Number of subjects: 523
Study 15189638 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 0
Study 10930484 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 106
Study 10930484 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 106
Study 10930484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both imaging studies
Number of subjects: 106
Study 9307129 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stimulation using a Peltier thermode heated to 45‐53 degrees C, applied in brief (700 ms) contacts at interstimulus intervals (ISIs) of 3 s.
Number of subjects: 0
Study 9307129 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stimulation at frequencies of > or = 0.33 Hz.
Number of subjects: 0
Study 9307129 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior administration of dextromethorphan (a N‐methyl‐D‐aspartate receptor antagonist).
Number of subjects: 0
Study 9307129 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating stimulation of adjacent but nonoverlapping skin sites at 0.33 Hz.
Number of subjects: 0
Study 8458045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (0.25, 0.5, 1, or 2 mg)
Number of subjects: 76
Study 8458045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 2942426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance with local anesthesia
Number of subjects: 120
Study 2942426 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy under general anesthesia
Number of subjects: 120
Study 28358570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunchtime park walks
Number of subjects: 97
Study 28358570 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 97
Study 28010731 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated research nurse, GCP training, trial-related training sessions for staff
Number of subjects: 508
Study 28010731 — intervention group
Group type: COMPARATOR
Intervention: Heavy clinical workload, shift patterns of work, inadequate number of trained staff, time and setting of consent seeking, non-availability of research staff out of hours, parents' concerns about experimental medicine
Number of subjects: 508
Study 24983199 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive sessions of formative self-testing (RFST)
Number of subjects: 196
Study 24983199 — intervention group
Group type: COMPARATOR
Intervention: Repetitive sessions of formative self-testing with additional practice (RFSTAP)
Number of subjects: 196
Study 23220798 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise intervention (moderate-intensity bicycle exercise for ∼40 min, 2.5 times per week)
Number of subjects: 131
Study 21660402 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (2 mg/kg/d, maximum 20 mg in 2 divided doses, for 5 days)
Number of subjects: 128
Study 21660402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 18434918 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system worn for 4 hours
Number of subjects: 0
Study 18434918 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system worn for 6 hours
Number of subjects: 0
Study 18434918 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate transdermal system (various doses: 10, 15, 20, or 30 mg) worn for 9 hours
Number of subjects: 0
Study 16544177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg deoxyspergualin (DSG)
Number of subjects: 44
Study 16544177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg deoxyspergualin (DSG)
Number of subjects: 44
Study 16544177 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of deoxyspergualin (DSG)
Number of subjects: 44
Study 14662279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 401
Study 14662279 — intervention group
Group type: EXPERIMENTAL
Intervention: Global assessment
Number of subjects: 401
Study 10718390 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergistic sedation with low-dose midazolam and propofol (group II), median dose of 2 mg midazolam and median 100 mg propofol (IQR 53 to 145) with a maximal bolus of 50 mg.
Number of subjects: 79
Study 10718390 — intervention group
Group type: COMPARATOR
Intervention: Standard combination of midazolam and nalbuphine (group I), median dose of 9 mg midazolam (IQR 6 to 12) and median 20 mg nalbuphine (IQR 10 to 20).
Number of subjects: 79
Study 9185636 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 1049
Study 9185636 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 20 mg
Number of subjects: 1049
Study 9185636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1049
Study 1350366 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 micrograms morning and evening)
Number of subjects: 96
Study 1350366 — intervention group
Group type: COMPARATOR
Intervention: Theophylline-ketotifen association (300 mg and 1 mg morning and evening)
Number of subjects: 96
Study 2969912 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24
Study 2969912 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 24
Study 31325107 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous postoperative pericardial flushing (CPPF) with 0.9% NaCl at 38 °C for up to 8 hours postoperative
Number of subjects: 42
Study 31325107 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-CPPF)
Number of subjects: 42
Study 29402651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunbeam Program (progressive resistance training plus balance exercise for 50 hours over 25 weeks)
Number of subjects: 221
Study 29402651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunbeam Program
Number of subjects: 221
Study 29402651 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 221
Study 27525532 — intervention group
Group type: EXPERIMENTAL
Intervention: SC administration of 20 mcg of teriparatide every 12 hours until discharge
Number of subjects: 26
Study 27525532 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 26
Study 25335656 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention group (study group)
Number of subjects: 696
Study 25335656 — intervention group
Group type: COMPARATOR
Intervention: Routine monitoring (control group)
Number of subjects: 696
Study 23075700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidcombe Program
Number of subjects: 10
Study 20979696 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy plus adjuvant chemotherapy
Number of subjects: 156
Study 20979696 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 156
Study 18850461 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 123
Study 18850461 — intervention group
Group type: COMPARATOR
Intervention: Coagulation of uterine arteries at their origin plus total laparoscopic hysterectomy (CUA + TLH)
Number of subjects: 123
Study 16263827 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin
Number of subjects: 44
Study 16263827 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg melatonin
Number of subjects: 44
Study 16263827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12610739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloride salt (8 mg/kg quinine base every 8 h by slow 4-h intravenous infusion)
Number of subjects: 48
Study 12610739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinchona alkaloid mixture (8 mg/kg quinine base every 8 h by slow 4-h intravenous infusion)
Number of subjects: 48
Study 12610739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloride salt (8 mg/kg quinine base every 8 h by intrarectal administration)
Number of subjects: 48
Study 12610739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinchona alkaloid mixture (8 mg/kg quinine base every 8 h by intrarectal administration)
Number of subjects: 48
Study 10353861 — intervention group
Group type: EXPERIMENTAL
Intervention: sc rIL-2 (3 x 10(6) IU once a day) with HAART
Number of subjects: 25
Study 10353861 — intervention group
Group type: COMPARATOR
Intervention: HAART alone (control group)
Number of subjects: 25
Study 8629065 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic therapy alone
Number of subjects: 65
Study 8629065 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic therapy plus antibiotics
Number of subjects: 65